$BIIB

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

Stoke Therapeutics and Biogen presented long-term data at the 16th European Epilepsy Congress, showing zorevunersen's potential in treating Dravet syndrome. The Phase 1/2a and OLE studies demonstrated durable seizure reductions, cognitive and behavioral improvements, and quality of life enhancements. The Phase 3 EMPEROR study data is expected in Q3 2027, aiming to complete the U.S. NDA submission. Zorevunersen was generally well tolerated, with some patients treated for over 5 years. Dravet synd

Biogen (BIIB) acquired RayThera, a biotech developing immunology therapies, following a Q2 earnings beat. The company raised its full-year revenue outlook but cut its EPS forecast due to acquisition-related charges. Biogen's older MS business is shrinking, while newer drugs like Leqembi and its rare-disease portfolio show growth. The company aims to shift focus to newer growth areas, but faces integration and execution risks.

Stoke Therapeutics (STOK) and Biogen (BIIB) presented 4-year data from Phase 1/2a studies of zorevunersen, an investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress. The data showed sustained improvements in cognition, behavior, and seizure reduction, with a generally well-tolerated safety profile. The Phase 3 EMPEROR study is ongoing, with results expected in Q3 2027.

Eisai and Biogen announced the U.S. availability of LEQEMBI IQLIK, a subcutaneous autoinjector for early Alzheimer's disease treatment. The 500 mg weekly injection offers convenience over IV dosing. Eisai leads development, with both companies co-commercializing. Support resources include an app and patient assistance programs.

Veeva Systems announced that Biogen and Regeneron Pharmaceuticals have adopted its Vault CRM platform. The companies will use the AI-driven system for global sales operations, aiming to improve patient access to treatments. Veeva sees this as part of a broader industry shift towards agentic commercial strategies. The deals highlight Veeva's push to migrate customers to its newer Vault CRM architecture. Financial terms and timelines were not disclosed.

Biogen has submitted a new offer for its drug Skyclarys to be covered by Ireland's HSE, which will be discussed by the HSE Senior Management Team. The drug, approved by the EMA and FDA, treats Friedreich's ataxia and was previously rejected on cost grounds. Biogen disputes the NCPE's cost estimates, citing a €280,000 annual cost per patient and a €134m-€163m five-year budget impact.

Eisai and Biogen announced the U.S. availability of LEQEMBI IQLIK, an autoinjector for initiating lecanemab-irmb treatment in early Alzheimer's disease. The subcutaneous injection offers at-home dosing, reducing clinic visits and healthcare resource use. The companies provide support resources for patients and healthcare providers.

LEO Pharma agreed to acquire worldwide rights to Tanabe Pharma’s dersimelagon for up to $435m. The late-stage oral drug completed Phase III, with an FDA NDA filed June 2026. Thermo Fisher and KYAN Technologies will collaborate on precision oncology using patient-derived tumoroids. Biogen’s felzartamab won China NMPA approval for multiple myeloma. Expedition Therapeutics raised $115m Series B for EXPD-101 COPD Phase II.

Fine Gael TDs met Biogen over Skyclarys for Friedreich’s Ataxia after Ireland’s HSE recommended against funding. Skyclarys was approved by the European Medicines Agency in Feb 2024 and costs about €288,000 per patient per year. Around 200 Irish patients lack access despite availability elsewhere. A letter from Fianna Fáil MPs urged Health Minister and HSE to reverse the decision.